Insider Trading June 1, 2026 01:52 PM

Diodes Corporate Secretary Sells Shares Amid Strong Earnings and Leadership Shifts

Analysis of insider selling activity juxtaposed with recent financial results and board changes at Diodes Inc.

By Derek Hwang DIOD

Corporate secretary Richard White sold a total value of $318,500 worth of Diodes Inc. common stock on May 29, 2026. This transaction occurred as the semiconductor company reported strong first-quarter financial results and announced a change in board leadership.The selling activity involved two separate sales: 1,000 shares at $104.48 per share and 2,000 shares at $107.0101 per share. Following the divestment, Mr. White retains a direct holding of 8,071 shares, in addition to an indirect stake through the BRW MGMT TRUST involving 34,304 shares.

Diodes Corporate Secretary Sells Shares Amid Strong Earnings and Leadership Shifts
DIOD

Key Points

  • Strong financial performance in Q1 2026
  • Leadership change with Angie Chen Button taking the Chairwoman role
  • The company's sustained profitability over 34 years

Analysis of insider transactions often provides insight into internal confidence levels and perceptions of valuation within a company. Recently, Richard White, Corporate Secretary at Diodes Inc. (NASDAQ:DIOD), executed a series of sales of the company's common stock on May 29, 2026.

Mr. White disposed of a combined total of 3,000 shares, representing a value of $318,500. The price points for these transactions varied, ranging from $104.48 to $107.0101 per share. This activity takes place while the stock is trading at $102.59, a level that reflects significant historical performance, including a 137% return over the past year for the semiconductor firm.

Details of the Stock Sales

The divestiture was structured across two distinct sales events. Initially, Mr. White sold 1,000 shares at $104.48 per share. Subsequently, a second transaction saw him sell an additional 2,000 shares at a price of $107.0101 per share.

Following the completion of these sales, Mr. White's direct ownership stake in Diodes Incorporated common stock stands at 8,071 shares. His total holdings also include an indirect position amounting to 34,304 shares, held through the BRW MGMT TRUST.

From a valuation standpoint, one analysis suggests that DIOD currently appears overvalued relative to its Fair Value, noting the availability of 14 additional ProTips for subscribers who wish to review this metric.


In parallel with the insider trading activity, Diodes Incorporated released strong financial data for the first quarter of 2026. The company reported earnings per share (EPS) of $0.43. This figure significantly surpassed the consensus analyst forecast of $0.34. Furthermore, revenue performance exceeded projections, reaching $405.5 million compared to a projected $395 million. These financial metrics underscore robust operational execution during the most recent quarter.

Beyond its financials, Diodes also announced changes within its leadership structure. Angie Chen Button was elected as Chairwoman of the Board. This transition follows the retirement of Dr. Keh-Shew Lu. During Dr. Lu's tenure, the company achieved substantial growth, expanding by over 500% and successfully completing ten acquisitions.

Despite these positive financial reports and leadership transitions, the stock exhibited a muted reaction during aftermarket trading. It is worth noting that Diodes has maintained profitability for thirty-four consecutive years, an enduring measure of its operational stability.


Risks

  • Insider selling by Corporate Secretary Richard White, suggesting potential internal valuation concerns.
  • Market reaction to positive earnings was muted in aftermarket trading.
  • Valuation analysis suggests the stock may be overvalued relative to its Fair Value.

More from Insider Trading

Rackspace Technology Executive Offloads Shares to Cover Tax Obligations Amid Stock Surge Jun 4, 2026 Fermi Inc. Executive Unloads $1M in Shares Amid Ongoing Corporate Restructuring Jun 4, 2026 Veracyte Executive Sells Nearly $700K in Shares Amid Product Rollouts and Analyst Upgrades Jun 4, 2026 Veracyte Executive Traces Share Disposition Amid Clinical Milestones and Valuation Scrutiny Jun 4, 2026 Veracyte CFO Executes $177K Stock Sale Amid Clinical Trial Updates and Analyst Revisions Jun 4, 2026